# A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

> **NCT01263704** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 42 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01263704
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-17
- **Primary completion:** 2017-04-03
- **Final completion:** 2017-04-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263704, "A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01263704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*